AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT03998072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Five session cognitive analytic therapy (CAT) consultancy
Description: Five session consultancy with patients and care coordinators using cognitive analytic therapy
Study NCT03768375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional chemotherapy(FORFIRINOX) combined with target agents
Description: Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib
Study NCT03768375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional chemotherapy(FORFIRINOX)
Description: conventional chemotherapy(FORFIRINOX)
Study NCT00712504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT00712504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
Study NCT00295802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Imaging High Intensity Focused Ultrasound
Study NCT03118466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
Study NCT03118466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
Study NCT00509691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT00509691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study NCT00409266 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Computer assisted navigation
Study NCT02905955 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prevena, KCI, Acelity, NPWT
Description: All patients will receive a Prevena NPWT (if inclusion criteria are met)
Study NCT02078843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gallium-68-DOTATATE PET/CT (index test)
Description: Somatostatin-based imaging tracer
Study NCT02078843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Indium-111-Octreoscan (standard test)
Description: Somatostatin-based imaging tracer
Study NCT02622776 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal DNA Collection
Description: Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
Study NCT03870217 — intervention group
Intervention type: BEHAVIORAL
Intervention: Site selection
Description: Turning off electrodes on the electrode array based on imaging and psychophysical measures
Study NCT01171807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dex 21-P
Description: At each procedure 50 ml of patient whole blood was washed with saline solution and centrifugated. The isolated erythrocytes were suspended into 2 hypotonic solutions to make their membrane permeable and incubated with Dex 21-P sodium salt up to obtain a final concentration of 10 mM. The drug loaded erythrocytes were immediately re-infused by using a suitable filter.
Study NCT01171807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to placebo arm performed the same procedure as the patients assigned to the DEX 21-P group without loading in the Red Blood Cells the Dex 21-P
Study NCT04083677 — intervention group
Intervention type: DEVICE
Intervention: SONAR
Description: A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.
Study NCT05016362 — intervention group
Intervention type: PROCEDURE
Intervention: medial fat preservation upper blepharoplasty
Description: medial fat preservation upper blepharoplasty increasing volumetric upper eyelid skin fold
Study NCT04394208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
Study NCT03118466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
Study NCT03118466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: It interfere with cell reproduction
Study NCT04550949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1206
Description: The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
Study NCT04550949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva
Description: The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
Study NCT05431868 — intervention group
Intervention type: OTHER
Intervention: AT LISA tri 839MP (Carl Zeiss Meditec AG)
Description: This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation.
Study NCT02398188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202
Study NCT02398188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01952249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: administered intravenously
Study NCT01952249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: administered intravenously
Study NCT04394208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT02138955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomeal curcumin
Study NCT00295802 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
Description: Cryotherapy
Study NCT00703937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Study NCT00703937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC) for the treatment of IDA
Study NCT03789448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Access to ART for All
Description: All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines
Study NCT04401501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Exercises
Description: Combination of physiotherapy (manual therapy) techniques and exercises for cervicogenic headache
Study NCT04401501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises for cervicogenic headache
Study NCT03913000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID-085
Description: Hard capsules for oral administration formulated at a strength of 200 mg
Study NCT00747175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
Study NCT00747175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension to a tolerable dose, 1 month treatment
Study NCT03997370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03997370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00370305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: 89 mg BID for 8 weeks, orally
Study NCT04513652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-920
Description: AG-920 Sterile Topical Ophthalmic Solution
Study NCT04513652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Topical Ophthalmic Solution
Study NCT04842929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
Study NCT02980315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: the patients treat with CAR-T cells
Study NCT04049461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone alkaline phosphatase
Description: Hematologic indicators reflecting ossification.
Study NCT04049461 — intervention group
Intervention type: RADIATION
Intervention: Abdominal CT scan
Description: Observe whether HOAI occurs.
Study NCT04611815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Participant will undergo robotic-assisted or conventional total knee arthroplasty
Study NCT04842929 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
Study NCT04611815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computer tomography scan
Description: CT scans of the affected knee joint before and after the surgical procedure
Study NCT04611815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: biomechanical assesment
Description: Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
Study NCT02324153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: 1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
Study NCT02324153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Placebo Comparator
Study NCT02324153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microcrystalline Cellulose
Description: Placebo Comparator
Study NCT02324153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riboflavin 100 mg
Description: Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
Study NCT03250234 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adequate Carbohydrate
Description: During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
Study NCT02324153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 100 mg
Description: Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
Study NCT02702544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioScreen 1000 - Haemodynamic Measurement System, Medis
Description: Impedance cardiography (ICG)
Study NCT02702544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System
Description: Blood pressure monitoring every 1 min during leg elevation
Study NCT03335176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance ad Resistance Training Exercise
Description: Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
Study NCT02249325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic dietary supplement
Description: Florajen3 is a commercially available probiotic supplement containing three bacteria of human origin (>7.5 x10\^9 L. acidophilus, >6.0 x10\^9 .B. lactis, and >1.5 x10\^9 B .longum). Once capsule was administered daily by mouth from 28 through 36 weeks gestation.
Study NCT04382482 — intervention group
Intervention type: DEVICE
Intervention: Tachidino
Description: Web-platform delivering remote treatment of reading and spelling disorders through the (visual or auditory) presentation of words and sentences to be either decoded or corrected (reordering wrong letter sequences).
Study NCT01776229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure, Relaxation, & Rescripting Therapy-Child
Description: Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
Study NCT01552486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Spinal Manipulative Therapy
Description: Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
Study NCT01552486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study NCT00781950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: 30 grams of milled flaxseed per day in food products or on its own.
Study NCT00781950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Wheat and Mixed Dietary Oils
Study NCT03250234 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Carbohydrate
Description: During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage.~For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion
Study NCT04780321 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)
Description: use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1
Study NCT04780321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 patients receipt placebo intravenous infusion on day 1
Study NCT01785381 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Added value of coordinator
Description: Added value of coordinator
Study NCT06525792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen and standard therapy were given
Study NCT06525792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Ozone and standard therapy were given
Study NCT06525792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Best standard of care
Study NCT05242211 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise test
Description: Each participants will conducted an exercise test on treadmill (using Modified Bruce Protocol) and cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange. 10 minute after the graded exercise test Supra maximal exercise test (SMT) will be done for 2 minutes one stage (treadmill protocol) or 10% at cycle protocol higher than highest load achieved in the incremental test.
Study NCT01434511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBI-1
Description: intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
Study NCT01949896 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NPO
Description: Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
Study NCT01949896 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group: continue feedings
Description: Feedings will be continued in this group.
Study NCT01484340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: The nicotine patch be given in three phases:~* 2 weeks of patches at enrollment~* 6 weeks of patches at two-week follow-up visit~* 2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg.
Study NCT01484340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Counseling
Description: The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~* Baseline~* 2-week follow-up (Quit Day)~* 1-month follow-up~* 2-month follow-up~* 3-month follow-up~* 6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again.
Study NCT02314013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin + Metronidazole
Description: intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
Study NCT03727282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjust dobutamine according to the ejection volume index
Description: adjust dobutamine dose
Study NCT03727282 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: adjust dobutamine according to the attending physician
Description: adjust dobutamine dose
Study NCT00877968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whole wheat banana bread
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g
Study NCT00877968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole pea flour banana bread
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g
Study NCT00877968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whole wheat biscotti
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g